Skip to content

L · 0DOL.L

Biofrontera AG

Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….

Sector
Healthcare · Drug Manufacturers - Specialty & Generic
Headquarters
Leverkusen 51377

Price at previous close

$2.65

Market cap 106.98M

Price history

The price history chart is shown only to users with a Pro subscription.

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for Biofrontera AG (0DOL.L) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

The valuation history chart is shown only to users with a Pro subscription.

Historic valuation ratios

Pick a category, then toggle metrics to compare.

Historic valuation ratios are shown only to users with a Pro subscription.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Biofrontera AG

        Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

        CEO
        Pilar de la Huerta Martinez
        Employees
        88
        Beta
        -0.17

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.